http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Rubius Therapeutics (RUBY) Issues Strategic Update
-
Rubius Therapeutics Announces Strategic Update
-
Rubius Therapeutics Announces Strategic Update
-
Rubius Therapeutics to Provide Strategic Update
-
Rubius Therapeutics to Provide Strategic Update
-
Senda Biosciences Announces Close of $123 Million Series C Financing
-
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
-
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
-
Rubius Therapeutics (RUBY) Appoints Susanne Schaffert to its Board
-
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
-
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
-
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
-
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
-
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
-
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
-
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
-
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
-
Rubius Therapeutics (RUBY) Appoints Noubar Afeyan as Board Chair
-
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors
-
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors
-
Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
-
Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
-
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
-
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
-
Rubius Therapeutics (RUBY) Announces Updated RTX-240 Clinical Data at AACR
-
Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activi
-
Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activi
-
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Soli
-
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Soli
-
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
-
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
-
Rubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
Rubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
-
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
-
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
-
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
-
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
-
Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
-
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
-
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
-
Rubius Therapeutics (RUBY) Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference
-
Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference
-
Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference
-
Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
-
Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
-
Rubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day
-
Rubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day
